Antares Pharma (Nasdaq: ATRS) shares fell about 8% today after the company disclosed an equity offering of 12.5 million shares. Dilution is a way of life for many small pharmaceutical companies, and with today's announced capital raise, Antares will receive about $47 million in net cash, more than doubling its cash balance from the end of last quarter. While shareholders will be left holding a smaller piece of the pie, the company is approaching an important milestone in the first quarter of 2013, and today's move seemed like reasonable timing given the 80% run that shares have seen year to date. Follow along in the following video as Fool.com health care bureau chief Brenton Flynn discusses the Antares news in more detail.
Are you on the lookout for the next big up-and-coming stock? If so, check out our free video report: "3 Stocks To Own For The New Industrial Revolution." In it, you'll learn about and incredible technology that could disrupt the "Made in China" era forever. Claim your report by clicking here now.